Amphista Therapeutics is the leading Europe-based targeted protein degradation (TPD) company. Our scientific team, which includes leading academic and drug discovery pioneers from the TPD field, has developed several completely novel mechanisms to remove disease-causing proteins from within cells.
We have shown these novel mechanisms have potential to overcome many of the limitations seen with current TPD approaches, and to deliver transformational medicines to treat a wide range of disease.